📚 Independent Educational Reviews & Comparisons — We Help You Understand Your STD Testing Options
    SafeSTDTest.com
    Back to Blog
    Testing Guides

    STD Test Window Periods Chart: When Each Infection Can Be Detected

    Oct 19, 2026 5 min readBy SafeSTDTest Editorial
    Chart showing approximate STI test window periods by infection and test type

    Use this US-focused STI testing window chart to understand approximate detection timing for HIV, chlamydia, gonorrhea, syphilis, herpes, and hepatitis C.

    Key takeaways

    • A window period is the time between a relevant exposure and when a specific test may detect an infection; it is not a guaranteed date of positivity.
    • Different HIV tests have different detection ranges, from approximately 10 days for a NAT to as long as 90 days for antibody tests.
    • Chlamydia and gonorrhea NAAT testing may need to be repeated 1–2 weeks after exposure if an initial test is negative and presumptive treatment was not provided.
    • Symptoms, a known exposure, pregnancy, or a recent possible HIV exposure warrant clinical advice regardless of the timing of a test.

    If you are searching for an STD test window periods chart, the most important answer is that there is no single testing day that works for every infection or every test. The window period is the time between a relevant exposure or infection and the point when a particular test may detect it. A negative result taken too early may not rule out infection.

    This chart provides approximate US guidance, not a guarantee that an infection will be detected on a specific day. Test type, specimen, exposed body site, symptoms, immune status, and clinical context can change what testing is appropriate.

    STD and STI test window periods chart

    • Nucleic acid testing (NAT): approximately 10–33 days after exposure. Laboratory antigen/antibody testing: approximately 18–45 days. Rapid finger-stick antigen/antibody testing: approximately 18–90 days. Antibody testing: approximately 23–90 days. The FDA describes the OraQuick home HIV test as an oral-fluid antibody self-test with an approximately three-month window-period limitation, and a reactive result requires confirmatory testing.
    • CDC guidance supports repeating a nucleic acid amplification test (NAAT) 1–2 weeks after exposure when the initial test is negative and presumptive treatment was not provided. The specimen and anatomical site should match the exposure; genital, rectal, or pharyngeal testing may be clinically appropriate.
    • As with chlamydia, CDC guidance supports repeating NAAT testing 1–2 weeks after exposure when an initial result is negative and presumptive treatment was not provided. Testing should account for the exposed anatomical site, including genital, rectal, or pharyngeal sites when appropriate.
    • Syphilis has an incubation period of approximately 10–90 days. Early serology can be nonreactive, so a negative early test may not exclude infection. Symptoms and the exposure history should be interpreted with the test result, and repeat testing may be needed when early infection remains possible.
    • Type-specific antibody tests can be falsely negative early. CDC recommends repeat type-specific antibody testing 12 weeks after presumed acquisition when recent HSV-2 infection is suspected, while CDC also notes that current tests may take 16 weeks or longer to detect infection after exposure. If lesions are present, lesion PCR or NAAT is preferred over screening blood tests.
    • HCV RNA may be detectable approximately 1–2 weeks after exposure. HCV antibodies may appear approximately 8–11 weeks after exposure, and antibody testing can miss early infection. RNA testing may be preferred in some recent-exposure situations.
    • CDC describes available tests, specimens, and performance characteristics, but the cited guidance does not establish one universal post-exposure window. A clinician can help select testing based on symptoms, exposure, and the available specimen.

    How to use the chart

    Start by identifying the infection being considered and the test used. An HIV NAT is not the same as an antibody self-test, and an HCV RNA test is not the same as an antibody test. The range in the chart describes when a test may detect infection, not when every infected person will receive a positive result.

    Next, consider the site of exposure. A urine or genital sample may not evaluate an infection at the throat or rectum. For chlamydia and gonorrhea, tell the clinician about oral, anal, and genital exposure so testing can be directed to the relevant anatomical sites. A broad commercial panel should not be assumed to test every infection or every exposed site.

    Finally, consider whether the test was performed during the window period. If an early result is negative, follow-up testing may be appropriate. The timing should be based on the infection, test type, exposure, symptoms, and professional guidance rather than a universal 7-, 14-, 30-, 45-, or 90-day rule.

    HIV testing timing depends strongly on the test

    CDC distinguishes NAT, laboratory antigen/antibody, rapid antigen/antibody, and antibody tests because they detect different markers. Laboratory testing and rapid testing therefore do not share one window period. The FDA explains that the OraQuick home HIV test is an oral-fluid antibody self-test with an approximately three-month window-period limitation. A reactive self-test is not by itself a final diagnosis and needs confirmatory testing.

    A possible recent HIV exposure can require time-sensitive medical evaluation. Do not wait for a routine testing date if you are concerned about a recent high-risk exposure; contact a clinician, urgent-care service, or public-health service promptly.

    Why herpes does not fit a simple chart

    Herpes testing requires special caution. When a person has a sore or blister, lesion PCR or NAAT is preferred to help identify HSV. Blood antibody testing can be falsely negative early and can also create interpretation problems. The USPSTF recommends against routine serologic screening for asymptomatic adolescents and adults because of limited accuracy, false-positive results, and uncertain benefit. A positive antibody result does not establish when or from whom infection was acquired.

    Infections without one universal window period

    Hepatitis B, HPV, and trichomoniasis should not be reduced to one simplistic consumer testing date. Hepatitis B timing depends on the specific serologic marker, vaccination status, baseline testing, and exposure circumstances. HPV cannot be ruled out through a general STI panel after a recent exposure. For trichomoniasis, the appropriate method and specimen depend on clinical circumstances, and the cited CDC guidance does not establish one universal post-exposure window.

    When to seek medical advice

    • Seek evaluation for sores, ulcers, rash, unusual discharge, pain with urination, pelvic or testicular pain, fever, or other concerning symptoms instead of waiting for a preferred testing date.
    • Discuss testing with a clinician after a known exposure, during pregnancy, or if you have an immunocompromising condition.
    • Ask whether testing should include genital, rectal, or throat specimens based on the sites involved.
    • If an early negative result does not fit the exposure or symptoms, ask whether repeat testing or another test method is appropriate.
    • Use current CDC screening recommendations and individualized clinical advice for routine screening, post-treatment retesting, and test-of-cure decisions; these are not the same as post-exposure window periods.

    The bottom line

    The best STD test window periods chart is test-specific, approximate, and tied to the exposed anatomical site. HIV, hepatitis C, chlamydia, gonorrhea, syphilis, and HSV each have different evidence and limitations. An early negative result may need follow-up, and symptoms or a known exposure deserve clinical attention regardless of the calendar.

    Frequently asked questions

    How soon after sex can an STI test detect an infection?

    It depends on the infection and test. CDC-supported examples include HIV NAT detection at approximately 10–33 days, HCV RNA detection at approximately 1–2 weeks, and repeat chlamydia or gonorrhea NAAT testing 1–2 weeks after exposure when an initial test is negative and presumptive treatment was not provided.

    Can one full-panel test detect every STD?

    No. Tests differ by infection, specimen, anatomical site, and timing. A urine or blood panel should not be assumed to evaluate every infection or every exposed site.

    Does a negative STI test during the window period rule out infection?

    No. Testing too early can produce a negative result before the relevant marker is detectable. Repeat testing or clinical evaluation may be needed.

    When should I test for herpes?

    If lesions are present, seek clinical evaluation for lesion PCR or NAAT. Blood antibody tests can be falsely negative early. CDC recommends repeat type-specific antibody testing 12 weeks after presumed acquisition when recent HSV-2 infection is suspected, while also noting that detection may take 16 weeks or longer.

    Is routine herpes blood screening recommended without symptoms?

    The USPSTF recommends against routine serologic screening for asymptomatic adolescents and adults because of limited accuracy, false-positive results, and uncertain benefit.

    Ready to compare testing options?

    Use our independent, educational comparisons to understand your online STD/STI testing options.

    View Provider Testing Options

    Affiliate link — we may earn a commission if you choose a provider through this link, at no extra cost to you. Pricing, turnaround and availability are set by the provider and can change.

    Related reading

    SafeSTDTest.com

    An independent educational and comparison resource for online STD/STI testing. We help you understand your options — we don't sell, perform, or fulfill tests ourselves.

    © 2026 SafeSTDTest.com. All rights reserved.

    Privacy considered Independent reviews Educational guides Plain-language

    SafeSTDTest.com is an independent educational and affiliate marketing resource. We do not sell, fulfill, or provide medical testing services directly. We review and compare online STD/STI testing options offered by third-party providers, and we may receive compensation when you choose a provider through our links, at no extra cost to you. Our affiliate partner offers lab-based testing. Provider features, pricing, availability, turnaround and certifications may change — always verify current details directly with the provider. The content provided is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

    Compare STD Testing Options